{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:22:05Z","timestamp":1794262925814,"version":"4.9.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma AG"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of frequently relapsing systemic autoimmune disorders characterized by vasculitis-related organ damage and multiple comorbidities related to chronic inflammation. Advances in immunosuppression-based therapies for AAV have considerably improved remission rates, reduced the risk of relapse, and improved survival in patients with AAV. However, mortality remains high compared with the general population and the benefits of treatment are often offset by treatment-related comorbidities, organ damage and adverse effects, particularly infections. The aim of this review is to investigate the key contributors to disease burden in patients with AAV and to describe strategies for improving health-related quality of life.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaf520","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:58:15Z","timestamp":1759406295000},"page":"i6-i11","source":"Crossref","is-referenced-by-count":2,"title":["Understanding the burden of ANCA-associated vasculitis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius KLINIKEN Kirchheim-Teck & N\u00fcrtingen, Akademisches Lehrkrankenhaus der Universit\u00e4t T\u00fcbingen , Kirchheim unter Teck,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026010901514457900_keaf520-B1","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3390\/ijms21197319","article-title":"Immunopathogenesis of ANCA-associated vasculitis","volume":"21","author":"Kronbichler","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026010901514457900_keaf520-B2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"2026010901514457900_keaf520-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026010901514457900_keaf520-B4","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes AVWG","year":"2024","journal-title":"Kidney Int"},{"key":"2026010901514457900_keaf520-B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf517","article-title":"Mapping a path forward: addressing disease burden, pathways and solutions in ANCA-associated vasculitis","author":"Hellmich","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514457900_keaf520-B6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"2026010901514457900_keaf520-B7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"S\u00e1nchez \u00c1lamo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514457900_keaf520-B8","doi-asserted-by":"crossref","first-page":"rkab018","DOI":"10.1093\/rap\/rkab018","article-title":"Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis","volume":"5","author":"King","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2026010901514457900_keaf520-B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026010901514457900_keaf520-B10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40674-017-0082-y","article-title":"Avoidance of harm from treatment for ANCA-associated vasculitis","volume":"3","author":"King","year":"2017","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2026010901514457900_keaf520-B11","doi-asserted-by":"crossref","first-page":"844112","DOI":"10.3389\/fmed.2022.844112","article-title":"Do relapses follow ANCA rises? A systematic review and meta-analysis on the value of serial ANCA level evaluation","volume":"9","author":"Al-Soudi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026010901514457900_keaf520-B12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/annrheumdis-2024-eular.27","article-title":"Increased risk of severe infection in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a population-based trend analysis","volume":"83","author":"Zhao","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026010901514457900_keaf520-B13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026010901514457900_keaf520-B14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/rheumatology\/keaa699","article-title":"Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study","volume":"60","author":"Rathmann","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514457900_keaf520-B15","doi-asserted-by":"crossref","first-page":"e19173","DOI":"10.1097\/MD.0000000000019173","article-title":"Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study","volume":"99","author":"Waki","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026010901514457900_keaf520-B16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026010901514457900_keaf520-B17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010901514457900_keaf520-B18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2026010901514457900_keaf520-B19","doi-asserted-by":"crossref","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"2026010901514457900_keaf520-B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026010901514457900_keaf520-B21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/ndt\/gfae018","article-title":"Long-term outcome of kidney function in patients with ANCA-associated vasculitis","volume":"39","author":"Sachez-Alamo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514457900_keaf520-B22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3899\/jrheum.151151","article-title":"Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population","volume":"43","author":"Englund","year":"2016","journal-title":"J Rheumatol"},{"key":"2026010901514457900_keaf520-B23","doi-asserted-by":"crossref","first-page":"e003956","DOI":"10.1136\/rmdopen-2023-003956","article-title":"Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis","volume":"10","author":"Scherbacher","year":"2024","journal-title":"RMD Open"},{"key":"2026010901514457900_keaf520-B24","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a Post hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026010901514457900_keaf520-B25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/rheumatology\/kead199","article-title":"Association of the AAV-PRO questionnaire with established outcome measures in AAV","volume":"63","author":"Maunz","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514457900_keaf520-B26","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.3390\/jcm10173773","article-title":"Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives","volume":"10","author":"Treppo","year":"2021","journal-title":"J Clin Med"},{"key":"2026010901514457900_keaf520-B27","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf520\/64519122\/keaf520.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/Supplement_1\/i6\/64519122\/keaf520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/Supplement_1\/i6\/64519122\/keaf520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:51:50Z","timestamp":1767941510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/65\/Supplement_1\/i6\/8275791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":27,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf520","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,6]]}}}